Skip to main content

Advertisement

SpringerLink
Log in

Is transarterial chemoembolization beneficial for patients with diffuse infiltrative hepatocellular carcinoma?

  • Original Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Purpose

Diffuse infiltrative hepatocellular carcinoma (D-HCC) is an incurable disease with short survival time. Transarterial chemoembolization (TACE) was often used to alleviate patient’s symptoms and reduce tumor burden. However, it remains unknown if the TACE benefits the survival of D-HCC patients.

Methods

A hospital-based retrospective study was conducted at a large referral hospital in Taiwan for a 9-year period (2000–2008).

Results

Of the 150 D-HCC patients, 106 patients were related to hepatitis B virus (HBV), 17 to hepatitis C virus (HCV), 3 to both HBV and HCV, and 24 not to HBV or HCV. Multivariate Cox regression analysis showed treatment strategy, serum alpha-fetoprotein level, model for end-stage liver disease (MELD) score, serum gamma glutamyl transferase, and serum lactic acid dehydrogenase were associated with survival time. Compared to supportive treatment, the adjusted hazard ratios of transarterial chemoembolization (TACE) and chemotherapy including oral or systemic chemotherapy were 0.383 (p < 0.001) and 0.711 (p = 0.289), respectively.

Conclusion

TACE is a preferred therapy for D-HCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Okuda K, Noguchi T, Kubo Y, et al. A clinical and pathological study of diffuse type hepatocellular carcinoma. Liver 1981;1:280–289

    Article  CAS  Google Scholar 

  2. Yuki K, Hirohashi S, Sakamoto M, et al. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer 1999;66:2174–2179

    Article  Google Scholar 

  3. Trevisani F, Caraceni P, Bernardi M, et al. Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer 1993;72:1557–1563

    Article  CAS  Google Scholar 

  4. Myung SJ, Yoon JH, Kim KM, et al. Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments. Hepatogastroenterology 2006;53:266–270

    PubMed  Google Scholar 

  5. Lee SD, Lee FY, Wu JC, et al. The prevalence of anti-hepatitis C virus among Chinese patients with hepatocellular carcinoma. Cancer 1992;69:342–345

    Article  CAS  Google Scholar 

  6. Chuang WL, Chang WY, Lu SN, et al. The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case–control study. Cancer 1992;69:2052–2054

    Article  CAS  Google Scholar 

  7. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208–1236

    Article  Google Scholar 

  8. Bruix J, Sherman M, Llovet JM, EASL Panel of Experts on HCC, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421–430

    Article  CAS  Google Scholar 

  9. Kanematsu M, Semelka RC, Leonardou P, et al. Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging 2003;18:189–195

    Article  Google Scholar 

  10. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91–96

    Article  Google Scholar 

  11. Stuart K, Tessitore J, Huberman M. 5-Fluorouracil and alpha-interferon in hepatocellular carcinoma. Am J Clin Oncol 1996;19:136–139

    Article  CAS  Google Scholar 

  12. Okazaki N, Yoshino M, Yoshida T, et al. Systemic chemotherapy of hepatocellular carcinoma. Gan To Kagaku Ryoho 1986;13:1584–1588

    CAS  PubMed  Google Scholar 

  13. Ihde DC, Matthews MJ, Makuch RW, et al. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival. Am J Med 1985;78:399–406

    Article  CAS  Google Scholar 

  14. Komorizono Y, Kohara K, Oketani M, et al. Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-alpha for advanced hepatocellular carcinoma: a pilot study. Dig Dis Sci 2003;48:877–881

    Article  CAS  Google Scholar 

  15. Boucher E, Corbinais S, Brissot P, et al. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 2002;50:305–308

    Article  CAS  Google Scholar 

  16. Noda I, Kitamoto M, Nakahara H, et al. Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol 2010;45:105–112

    Article  Google Scholar 

  17. Oka H, Saito A, Ito K, et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol 2001;16:1378–1383

    Article  CAS  Google Scholar 

  18. Sterling RK, Jeffers L, Gordon F, et al. Clinical utility of AFP-L3 % measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol 2007;102:2196–2205

    Article  Google Scholar 

  19. Leerapun A, Suravarapu SV, Bida JP, et al. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol 2007;5:394–402

    Article  CAS  Google Scholar 

  20. Marrero JA, Su GL, Wei W, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003;37:1114–1121

    Article  CAS  Google Scholar 

  21. Nakamura S, Nouso K, Sakaguchi K, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006;101:2038–2043

    Article  CAS  Google Scholar 

  22. Volk ML, Hernandez JC, Su GL, et al. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark 2007;3:79–87

    Article  CAS  Google Scholar 

  23. Sawabe M, Nakamura T, Kanno J, et al. Analysis of morphological factors of hepatocellular carcinoma in 98 autopsy cases with respect to pulmonary metastasis. Acta Pathol Jpn 1987;37:1389–1404

    CAS  PubMed  Google Scholar 

  24. Shijo H, Okazaki M, Higashihara H, et al. Hepatocellular carcinoma: a multivariate analysis of prognostic features in patients treated with hepatic arterial embolization. Am J Gastroenterol 1992;87:1154–1159

    CAS  PubMed  Google Scholar 

  25. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164–1171

    Article  CAS  Google Scholar 

  26. Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995;197:101–108

    Article  CAS  Google Scholar 

  27. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429–442

    Article  CAS  Google Scholar 

  28. Ohto M, Yoshikawa M, Saisho H, et al. Nonsurgical treatment of hepatocellular carcinoma in cirrhotic patients. World J Surg 1995;19:42–46

    Article  CAS  Google Scholar 

  29. Seror O, N’Kontchou G, Haddar D, et al. Large infiltrative hepatocellular carcinomas: treatment with percutaneous intraarterial ethanol injection alone or in combination with conventional percutaneous ethanol injection. Radiology 2005;234:299–309

    Article  Google Scholar 

  30. Jeon SH, Park KS, Kim YH, et al. Incidence and risk factors of acute hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma. Korean J Gastroenterol 2007;50:176–182

    PubMed  Google Scholar 

  31. Carr BI, Irish W, Federle MP. Chemoembolization for unresectable hepatocellular carcinoma in patients with or without portal vein thrombosis. Hepatogastroenterology 2010;57:1375–1381

    PubMed  Google Scholar 

  32. Hsu KY, Chau GY, Lui WY, et al. Predicting morbidity and mortality after hepatic resection in patients with hepatocellular carcinoma: the role of model for end-stage liver disease score. World J Surg 2009;33:2412–2419

    Article  Google Scholar 

  33. Iacob S, Gheorghe L, Iacob R, et al. MELD exceptions and new predictive score of death on long waiting lists for liver transplantation. Chirurgia 2009;104:267–273

    CAS  PubMed  Google Scholar 

  34. Limquiaco JL, Wong GL, Wong VW, et al. Evaluation of model for end stage liver disease (MELD)-based systems as prognostic index for hepatocellular carcinoma. J Gastroenterol Hepatol 2009;24:63–39

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Department of Medicine, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan, Republic of China

    Tsung-Hsing Hung

  2. School of Medicine, Tzu Chi University, Hualien, Taiwan, Republic of China

    Tsung-Hsing Hung & Chen-Chi Tsai

  3. Division of Infectious Disease, Department of Medicine, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan, Republic of China

    Chen-Chi Tsai

  4. Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, and National Yang-Ming School of Medicine, No-201, Sec 2, Shih-Pai Road, Taipei, Taiwan, 11217, Republic of China

    Tsung-Hsing Hung, Chung-Chi Lin, Hsing-Feng Lee, Chi-Jen Chu & Han-Chieh Lin

Authors
  1. Tsung-Hsing Hung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chen-Chi Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chung-Chi Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hsing-Feng Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chi-Jen Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Han-Chieh Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chi-Jen Chu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hung, TH., Tsai, CC., Lin, CC. et al. Is transarterial chemoembolization beneficial for patients with diffuse infiltrative hepatocellular carcinoma?. Hepatol Int 7, 676–682 (2013). https://doi.org/10.1007/s12072-012-9392-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-012-9392-1

Keywords

Search

Navigation